200 related articles for article (PubMed ID: 36721173)
1. Conversion surgery for advanced hepatocellular carcinoma after combination treatment of lenvatinib and camrelizumab: a case report.
Chen Z; Chen Z; Fan W; Zou Y; Zhang Y; Shi N; Jin H
World J Surg Oncol; 2023 Jan; 21(1):29. PubMed ID: 36721173
[TBL] [Abstract][Full Text] [Related]
2. Modified Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab for Advanced HCC: Two Case Reports.
Tian Y; Jin W; Sun H; Jin D; Kang D; Li Z; Piao L
J Hepatocell Carcinoma; 2023; 10():1587-1593. PubMed ID: 37791067
[TBL] [Abstract][Full Text] [Related]
3. A Multidisciplinary Treatment Strategy With Conversion Surgery for Hepatocellular Carcinoma.
Shiozaki H; Furukawa K; Haruki K; Matsumoto M; Uwagawa T; Onda S; Yamahata Y; Ishizaki S; Abe K; Fujioka S; Nakaseko Y; Okamoto T; Ikegami T
Anticancer Res; 2023 Apr; 43(4):1761-1766. PubMed ID: 36974796
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.
Xia Y; Tang W; Qian X; Li X; Cheng F; Wang K; Zhang F; Zhang C; Li D; Song J; Zhang H; Zhao J; Yao A; Wu X; Wu C; Ji G; Liu X; Zhu F; Qin L; Xiao X; Deng Z; Kong X; Li S; Yu Y; Xi W; Deng W; Qi C; Liu H; Pu L; Wang P; Wang X
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35379737
[TBL] [Abstract][Full Text] [Related]
5. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors.
Arita J; Ichida A; Nagata R; Mihara Y; Kawaguchi Y; Ishizawa T; Akamatsu N; Kaneko J; Hasegawa K
J Hepatobiliary Pancreat Sci; 2022 Jul; 29(7):732-740. PubMed ID: 35306748
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment Neutrophil-to-Lymphocyte Ratio as Prognostic Biomarkers in Patients with Unresectable Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab.
Xiao Y; Zhu G; Xie J; Luo L; Deng W; Lin L; Tao J; Hu Z; Shan R
J Hepatocell Carcinoma; 2023; 10():2049-2058. PubMed ID: 37965074
[TBL] [Abstract][Full Text] [Related]
7. [A Case of Unresectable Hepatocellular Carcinoma Treated using Lenvatinib and Conversion Surgery].
Utsunomiya T; Sakamoto K; Iwata M; Ito C; Sakamoto A; Matsui T; Shine M; Nishi Y; Uraoka M; Nagaoka T; Tamura K; Funamizu N; Ogawa K; Kitazawa R; Takada Y
Gan To Kagaku Ryoho; 2022 Dec; 49(12):1365-1367. PubMed ID: 36539251
[TBL] [Abstract][Full Text] [Related]
8. The Outcome of Conversion Liver Resection Surgery by Lenvatinib Treatment: A Single Center Experience.
Hidaka M; Hara T; Soyama A; Sasaki R; Matsushima H; Tanaka T; Hamada T; Imamura H; Adachi T; Kanetaka K; Miyaaki H; Okano S; Eguchi S
Anticancer Res; 2022 Jun; 42(6):3049-3054. PubMed ID: 35641262
[TBL] [Abstract][Full Text] [Related]
9. A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma.
Huang J; Liang R; Lu C; Lu L; Li S; Tang M; Huang X; Huang S; Mai R; Gao X; Li S; Zeng C; Lin Y; Ye J
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686291
[TBL] [Abstract][Full Text] [Related]
10. Conversion Hepatectomy for Huge Hepatocellular Carcinoma With Arterioportal Shunt After Chemoembolization and Lenvatinib Therapy.
Sato N; Beppu T; Kinoshita K; Yuki H; Suyama K; Chiyonaga S; Motohara T; Komohara Y; Hara A; Akahoshi S
Anticancer Res; 2019 Oct; 39(10):5695-5701. PubMed ID: 31570469
[TBL] [Abstract][Full Text] [Related]
11. Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma.
Guo Y; Ren Y; Chen L; Sun T; Zhang W; Sun B; Zhu L; Xiong F; Zheng C
BMC Cancer; 2022 Mar; 22(1):270. PubMed ID: 35287627
[TBL] [Abstract][Full Text] [Related]
12. Criteria for identifying potentially resectable patients with initially oncologically unresectable hepatocellular carcinoma before treatment with lenvatinib plus an anti-PD-1 antibody.
Xu B; Zhu XD; Shen YH; Zhu JJ; Liu J; Li ML; Tang PW; Zhou J; Fan J; Sun HC; Huang C
Front Immunol; 2022; 13():1016736. PubMed ID: 36505445
[TBL] [Abstract][Full Text] [Related]
13. A case of conversion hepatectomy for huge ruptured hepatocellular carcinoma after transarterial embolization and lenvatinib therapy.
Naganuma A; Suzuki Y; Hoshino T; Yasuoka H; Tamura Y; Naruse H; Tanaka H; Hirai K; Sakamoto I; Ogawa T; Hatanaka T; Kakizaki S
Clin J Gastroenterol; 2022 Feb; 15(1):177-184. PubMed ID: 34811701
[TBL] [Abstract][Full Text] [Related]
14. Case report: Conversion therapy to permit resection of initially unresectable hepatocellular carcinoma.
Chen K; Luo CP; Ge DX; Wang KL; Luo Q; Li YZ; You XM; Xiang BD; Li LQ; Ma L; Zhong JH
Front Oncol; 2022; 12():946693. PubMed ID: 36276151
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Impact of Surgical Intervention After Lenvatinib Treatment for Advanced Hepatocellular Carcinoma.
Shindoh J; Kawamura Y; Kobayashi Y; Kobayashi M; Akuta N; Okubo S; Suzuki Y; Hashimoto M
Ann Surg Oncol; 2021 Nov; 28(12):7663-7672. PubMed ID: 33904001
[TBL] [Abstract][Full Text] [Related]
16. Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study.
Wei F; Huang Q; He J; Luo L; Zeng Y
Cancer Manag Res; 2021; 13():4233-4240. PubMed ID: 34079375
[TBL] [Abstract][Full Text] [Related]
17. Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report.
Yokoo H; Takahashi H; Hagiwara M; Iwata H; Imai K; Saito Y; Matsuno N; Furukawa H
World J Hepatol; 2020 Dec; 12(12):1349-1357. PubMed ID: 33442460
[TBL] [Abstract][Full Text] [Related]
18. Conversion Surgery for Hepatocellular Carcinoma Following Molecular Therapy.
Yamamura K; Beppu T; Miyata T; Okabe H; Nitta H; Imai K; Hayashi H; Akahoshi S
Anticancer Res; 2022 Jan; 42(1):35-44. PubMed ID: 34969706
[TBL] [Abstract][Full Text] [Related]
19. [Clinical efficacy and safety analysis of camrelizumab combined with apatinib as a second-line therapy for unresectable hepatocellular carcinoma: a multicenter retrospective study].
Yuan GS; He WM; Hu XY; Li Q; Zang MY; Cheng X; Huang W; Ruan J; Wang JJ; Hou JL; Chen JZ
Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):326-331. PubMed ID: 33979958
[No Abstract] [Full Text] [Related]
20. Efficacy and Safety of Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Living Donor Liver Transplantation: A Report of Two Cases.
Ichida A; Akamatsu N; Nagata R; Mihara Y; Kawaguchi Y; Bae SK; Ishizawa T; Kaneko J; Arita J; Hasegawa K
Anticancer Res; 2022 Feb; 42(2):1161-1167. PubMed ID: 35093921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]